Breaking News Instant updates and real-time market news.

VRTX

Vertex

$155.69

2.62 (1.71%)

12:58
01/08/18
01/08
12:58
01/08/18
12:58

Vertex sees tezacaftor-ivacaftor combination approval in 2H in Europe

  • 08

    Jan

  • 31

    Jan

  • 28

    Feb

VRTX Vertex
$155.69

2.62 (1.71%)

01/03/18
JEFF
01/03/18
NO CHANGE
Target $185
JEFF
Buy
Vertex competitor's cystic fibrosis update unsurprising, says Jefferies
Jefferies analyst Michael Yee says last night's cystic fibrosis update from Vertex Pharmaceuticals (VRTX) competitor Galapagos NV (GLPG) contained no surprises. None of Galapagos' developments are unexpected, and 2018 remains a period where the Vertex competitor is running a number of "proof of concept" studies to see if it has something, Yee tells investors in a research note. He believes challenges remain for cystic fibrosis competitors because making a triple requires three individual drugs to show minimal drug-drug interactions and have a clean side effect profile. Yee keeps a Buy rating on Vertex with a $185 price target.
01/04/18
OPCO
01/04/18
NO CHANGE
Target $190
OPCO
Outperform
Vertex price target raised to $190 from $175 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Vertex to $190 from $175 based on heightened certainty of a strong tezacaftor/ivacaftor launch. The analyst notes that his survey of 25 high-volume pulmonologists validates Vertex's stated strategy to grow the total cystic fibrosis patients currently receiving a corrector/potentiator like Orkambi by adding another doublet, that there is a bolus of patients already awaiting tezacaftor/ivacaftor, and heterozygous F508del/residual function cystic fibrosis patients could be put on tezacaftor/ivacaftor quickly. He reiterates an Outperform rating on the shares.
01/05/18
BOFA
01/05/18
UPGRADE
BOFA
Buy
Vertex upgraded to Buy from Neutral at BofA/Merrill
01/05/18
BOFA
01/05/18
UPGRADE
Target $180
BOFA
Buy
Vertex upgraded to Buy, an 'enviable monopoly,' says BofA/Merrill
BofA/Merrill analyst Ying Huang upgraded Vertex to Buy from Neutral and increased its price target to $180 from $76 telling investors the company is a "winner" with an anticipated strong launch of Tex/IVA and positive Phase 2/3 date in cycstic fibrosis. Huang has an "enviable monopoly with pricing power as well as a substantial lead in the clinic.

TODAY'S FREE FLY STORIES

RDCM

Radcom

$19.65

0.25 (1.29%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Conference/Events
Radcom management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 24

    May

  • 29

    May

INFO

IHS Markit

$51.60

0.13 (0.25%)

05:52
05/22/18
05/22
05:52
05/22/18
05:52
Upgrade
IHS Markit rating change  »

IHS Markit upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTM

Quantum

$3.62

-0.06 (-1.63%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTEX

OpenText

$34.10

0.1 (0.29%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.60

0.6 (1.00%)

05:50
05/22/18
05/22
05:50
05/22/18
05:50
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

M

Macy's

$34.60

0.63 (1.85%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Upgrade
Macy's rating change  »

Macy's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$31.30

0.11 (0.35%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Conference/Events
NCR Corp. management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

, PFE

Pfizer

$35.79

0.15 (0.42%)

05:44
05/22/18
05/22
05:44
05/22/18
05:44
Hot Stocks
Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial »

Spark Therapeutics (ONCE)…

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

PFE

Pfizer

$35.79

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

FMC

FMC Corporation

$91.30

-0.22 (-0.24%)

05:41
05/22/18
05/22
05:41
05/22/18
05:41
Hot Stocks
FMC Corporation awarded contract for two fertilizer plants in India »

TechnipFMC, in consortium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$5.17

0.05 (0.98%)

05:40
05/22/18
05/22
05:40
05/22/18
05:40
Hot Stocks
Sprint partners with Scopeworker on multi-billion dollar 5G depoloyment »

Scopeworker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSHD

Goosehead Insurance

$16.19

0.12 (0.75%)

05:39
05/22/18
05/22
05:39
05/22/18
05:39
Initiation
Goosehead Insurance initiated  »

Goosehead Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$20.00

0.14 (0.70%)

05:38
05/22/18
05/22
05:38
05/22/18
05:38
Initiation
Smartsheet initiated  »

Smartsheet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

VLRS

Volaris

$5.42

-0.05 (-0.91%)

05:19
05/22/18
05/22
05:19
05/22/18
05:19
Recommendations
Volaris analyst commentary  »

Volaris price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAX

Baxter

$72.08

1.4603 (2.07%)

05:16
05/22/18
05/22
05:16
05/22/18
05:16
Recommendations
Baxter analyst commentary  »

Baxter buybacks should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOCU

DocuSign

$43.06

-1.73 (-3.86%)

05:08
05/22/18
05/22
05:08
05/22/18
05:08
Initiation
DocuSign initiated  »

DocuSign initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

AROC

Archrock

$12.30

0.35 (2.93%)

05:07
05/22/18
05/22
05:07
05/22/18
05:07
Recommendations
Archrock analyst commentary  »

Archrock added to Alpha…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$23.60

-0.065 (-0.27%)

05:05
05/22/18
05/22
05:05
05/22/18
05:05
Recommendations
Pure Storage analyst commentary  »

Pure Storage weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 07

    Jun

  • 12

    Jun

  • 10

    Jul

DOCU

DocuSign

$43.06

-1.73 (-3.86%)

05:02
05/22/18
05/22
05:02
05/22/18
05:02
Initiation
DocuSign initiated  »

DocuSign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

SSL

Sasol

$37.93

0.05 (0.13%)

05:00
05/22/18
05/22
05:00
05/22/18
05:00
Downgrade
Sasol rating change  »

Sasol downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSHD

Goosehead Insurance

$16.19

0.12 (0.75%)

04:58
05/22/18
05/22
04:58
05/22/18
04:58
Initiation
Goosehead Insurance initiated  »

Goosehead Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXTR

Extreme Networks

$9.16

-0.02 (-0.22%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Extreme Networks management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 29

    May

ALG

Alamo Group

$100.36

1.34 (1.35%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Alamo Group management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ALNA

Allena Pharmaceuticals

$15.99

-0.01 (-0.06%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Allena Pharmaceuticals management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.